Benzinga | Aug 4, 2021 11:23AM EDT

Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

* The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) ADX-2191 to treat retinitis pigmentosa (RP).

* ADX-2191 is a methotrexate for intravitreal injection.

* Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.

* Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.

* Related content: Benzinga's Full FDA Calendar.